



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T: 91 80 2808 2808
F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

BIO/SECL/AJ/2023-24/24

May 16, 2023

To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code – 532523	Scrip Symbol - Biocon

Subject: Intimation of the Earnings Call with analysts/investors under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 read with Para A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith intimation of Earnings Conference Call for analysts/investors on Wednesday, May 24, 2023.

The above-mentioned information will also be available on website of the Company at www.biocon.com.

Request you to take the above intimation on record.

Thanking You,

For **Biocon Limited**

Mayank Verma
Company Secretary and Compliance Officer
Membership No.: ACS 18776

Encl: As above



20th K.M. Hosur Road, Electronics City, Bangalore 560 100

Bangalore, May 16, 2023

Biocon's Q4 and full year ended FY 2023 Results Conference Call

At 9.00 am IST on May 24, 2023

The management team of Biocon Limited (BSE code: 532523, NSE Id: BIOCON) will organize a conference call for Analysts and Investors following the announcement of financial results for the quarter and year ended March 31, 2023. The call will be conducted over Zoom.

Conference Call Details	
Date	Wednesday, May 24, 2023
Time	9:00hrs -10:30hrs, IST
Registration Link	Click here
Recording	Will be made available within 24 hrs from the end of the call on the Company website (Biocon > Investors > Financial Information > Earnings Call Recordings)
Conference Call Transcript	Will be made available within 5 working days from the call date on the Company website (Biocon > Investors > Financial Information > Earnings Call Transcripts)

Note: Participants are requested to join 5 minutes in advance of the call start time.

For further information please contact:

Saurabh Paliwal

Investor Relations – Biocon Limited

P: +91 80 2808 2040/ +91 95383 80801

E: saurabh.paliwal@biocon.com

Safe Harbor: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current assumptions and expectations concerning future developments and their potential effects upon Biocon and its subsidiaries/associates. There can be no assurance that future developments affecting Biocon and its subsidiaries/associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties that may cause actual results to differ, possibly materially, from those contemplated by such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our Company, our directors, nor any of our subsidiaries/ associates assume any obligation to update or otherwise revise any statements reflecting circumstances arising after the conference call's conclusion to reflect the occurrence of underlying events, even if the underlying assumptions and expectations do not come to fruition.